{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:04:57Z","timestamp":1791493497175,"version":"4.3.4"},"reference-count":140,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review provides updates on juvenile dermatomyositis pathogenesis and treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>JDM pathogenesis research updates in genetic risk factors include C4 copy number. Studies clarify myositis-specific autoantibodies\u2019 (MSA) role in disease pathogenesis and more myositis-associated antibody (MAA) clinical associations. Recent studies validate an interferon (IFN)-regulated gene score and an IFN-related monocyte surface protein marker, SIGLEC-1. Vasculopathy and mitochondrial dysfunction evidence increases, both with ties to IFN. Studies point to not only T and B cells, but monocytes, macrophages, and neutrophils as dysregulated in JDM. Regarding treatment, there are growing reports of success with therapies targeting IFN-signaling (Janus kinase inhibitors), dazukibart (anti-IFN-beta), and anifrolumab (anti-IFNAR1). Chimeric antigen receptor (CAR) T-cell therapy targeting B-cells in a growing number of adult myositis patients and one JDM patient have dramatic reports of achieving drug-free remission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Growing evidence show genetic markers, MSA, IFN, vasculopathy, varied immune cells, and mitochondrial dysfunction having important roles in JDM pathogenesis. Some refractory patients show benefit with newer IFN pathway-targeted therapies and cellular CAR-T-cell therapy. Further collaborative research on disease pathogenesis, treatment targets, and innovate clinical trial design is needed to increase access to more efficacious treatments in JDM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001112","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T14:22:06Z","timestamp":1753194126000},"page":"445-456","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Updates in juvenile dermatomyositis: pathogenesis and therapy"],"prefix":"10.1097","volume":"37","author":[{"given":"Samantha L.","family":"Coss","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Pediatrics, Nationwide Children's Hospital, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Sabbagh","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kim","sequence":"additional","affiliation":[{"name":"Juvenile Myositis Pathogenesis and Therapeutics Unit, National Institute of Arthritis Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"R1-20251007","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","article-title":"Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care","volume":"19","author":"Papadopoulou","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"R2-20251007","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/art.43088","article-title":"Genetic architecture of idiopathic inflammatory myopathies from meta-analyses","volume":"77","author":"Zhu","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R3-20251007","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","article-title":"Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups","volume":"75","author":"Rothwell","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R4-20251007","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/gene.2015.28","article-title":"Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes","volume":"16","author":"Miller","year":"2015","journal-title":"Genes Immun"},{"key":"R5-20251007","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/BOR.0000000000000652","article-title":"Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis","volume":"31","author":"Rothwell","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R6-20251007","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.md.0000217525.82287.eb","article-title":"Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-a, -b, -cw, -drb1, and -dqa1 allelic profiles distinguish European American patients with different myositis autoantibodies","volume":"85","author":"O\u2019Hanlon","year":"2006","journal-title":"Medicine (Baltimore)"},{"key":"R7-20251007","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/art.1780390910","article-title":"Interrelationship of major histocompatibility complex class ii alleles and autoantibodies in four ethnic groups with various forms of myositis","volume":"39","author":"Arnett","year":"1996","journal-title":"Arthritis Rheum"},{"key":"R8-20251007","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.semarthrit.2019.03.005","article-title":"Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients","volume":"49","author":"Kang","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R9-20251007","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.23113","article-title":"Association of anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies with drb1*07:01 and severe myositis in juvenile myositis patients","volume":"69","author":"Kishi","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R10-20251007","doi-asserted-by":"crossref","first-page":"104804","DOI":"10.1016\/j.ebiom.2023.104804","article-title":"Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies","volume":"96","author":"Leclair","year":"2023","journal-title":"EBioMedicine"},{"key":"R11-20251007","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2018-214127","article-title":"Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases","volume":"78","author":"Acosta-Herrera","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R12-20251007","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/ard-2022-222935","article-title":"Low copy numbers of complement C4 and C4a deficiency are risk factors for myositis, its subgroups and autoantibodies","volume":"82","author":"Zhou","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R13-20251007","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1136\/annrheumdis-2015-207762","article-title":"Gene copy-number variations (CNVS) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis","volume":"75","author":"Lintner","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R14-20251007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0198-8859(88)90049-3","article-title":"C4 complement allotypes in juvenile dermatomyositis","volume":"22","author":"Robb","year":"1988","journal-title":"Hum Immunol"},{"key":"R15-20251007","first-page":"331","article-title":"C4 null genes in American whites and blacks with myositis","volume":"17","author":"Moulds","year":"1990","journal-title":"J Rheumatol"},{"key":"R16-20251007","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1080\/25785826.2024.2370083","article-title":"Low serum complements in idiopathic inflammatory myositis: clinical features and impact on the prognosis","volume":"47","author":"Nomura","year":"2024","journal-title":"Immunol Med"},{"key":"R17-20251007","doi-asserted-by":"crossref","first-page":"e14986","DOI":"10.1111\/exd.14986","article-title":"Epigenetic mechanisms driving the pathogenesis of systemic lupus erythematosus, systemic sclerosis and dermatomyositis","volume":"33","author":"Zhang","year":"2024","journal-title":"Exp Dermatol"},{"key":"R18-20251007","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00251-024-01350-y","article-title":"Decoding the genetic landscape of juvenile dermatomyositis: insights from phosphorylation-associated single nucleotide polymorphisms","volume":"76","author":"Zhang","year":"2024","journal-title":"Immunogenetics"},{"key":"R19-20251007","doi-asserted-by":"crossref","first-page":"2419117","DOI":"10.1080\/08916934.2024.2419117","article-title":"Genome-wide identification of cell type-specific susceptibility genes for juvenile dermatomyositis through the analysis of n(6)-methyladenosine-associated SNPs","volume":"57","author":"Zhang","year":"2024","journal-title":"Autoimmunity"},{"key":"R20-20251007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"R21-20251007","doi-asserted-by":"crossref","first-page":"C253","DOI":"10.1152\/ajpcell.00321.2019","article-title":"Multiple poloxamers increase plasma membrane repair capacity in muscle and nonmuscle cells","volume":"318","author":"Kwiatkowski","year":"2020","journal-title":"Am J Physiol Cell Physiol"},{"key":"R22-20251007","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"R23-20251007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/rir-2022-0001","article-title":"Myositis-specific antibodies: overview and clinical utilization","volume":"3","author":"Halilu","year":"2022","journal-title":"Rheumatol Immunol Res"},{"key":"R24-20251007","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40674-020-00168-5","article-title":"Juvenile dermatomyositis: new clues to diagnosis and therapy","volume":"7","author":"Pachman","year":"2021","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"R25-20251007","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.rdc.2021.07.003","article-title":"Updates on juvenile dermatomyositis from the last decade: classification to outcomes","volume":"47","author":"Kim","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"key":"R26-20251007","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11926-025-01188-7","article-title":"Anti melanoma differentiation-associated gene 5 antibody positive dermatomyositis: recent progress in pathophysiology and treatment","volume":"27","author":"Yoshida","year":"2025","journal-title":"Curr Rheumatol Rep"},{"key":"R27-20251007","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14397595.2018.1452353","article-title":"Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies","volume":"29","author":"Ueki","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R28-20251007","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CPM.0000000000000171","article-title":"The diagnosis and treatment of antisynthetase syndrome","volume":"23","author":"Witt","year":"2016","journal-title":"Clin Pulm Med"},{"key":"R29-20251007","doi-asserted-by":"crossref","first-page":"1439807","DOI":"10.3389\/fimmu.2024.1439807","article-title":"Pathogenic mechanisms of disease in idiopathic inflammatory myopathies: autoantibodies as clues","volume":"15","author":"Wu","year":"2024","journal-title":"Front Immunol"},{"key":"R30-20251007","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11926-024-01164-7","article-title":"Recent updates on the pathogenesis of inflammatory myopathies","volume":"26","author":"Musai","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"R31-20251007","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/annrheumdis-2019-216599","article-title":"Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis","volume":"79","author":"Pinal-Fernandez","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R32-20251007","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","volume":"83","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R33-20251007","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/annrheumdis-2020-218661","article-title":"Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1\u03b3 can result in experimental myositis","volume":"80","author":"Okiyama","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R34-20251007","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaut.2007.07.005","article-title":"Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation","volume":"29","author":"Katsumata","year":"2007","journal-title":"J Autoimmun"},{"key":"R35-20251007","doi-asserted-by":"crossref","first-page":"e2313070121","DOI":"10.1073\/pnas.2313070121","article-title":"Autoimmunity against melanoma differentiation-associated gene 5 induces interstitial lung disease mimicking dermatomyositis in mice","volume":"121","author":"Ichimura","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R36-20251007","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12931-023-02362-0","article-title":"Enhanced immune complex formation in the lungs of patients with dermatomyositis","volume":"24","author":"Zaizen","year":"2023","journal-title":"Respir Res"},{"key":"R37-20251007","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/1346-8138.17142","article-title":"Murine models of idiopathic inflammatory myopathies","volume":"51","author":"Okiyama","year":"2024","journal-title":"J Dermatol"},{"key":"R38-20251007","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Antiro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R39-20251007","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.42813","article-title":"Myositis-associated autoantibodies in patients with juvenile myositis are associated with refractory disease and mortality","volume":"76","author":"Sherman","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R40-20251007","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.41088","article-title":"Myositis autoantibodies: a comparison of results from the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot","volume":"72","author":"Mecoli","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R41-20251007","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R42-20251007","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/annrheumdis-2018-214690","article-title":"Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies","volume":"78","author":"Espinosa-Ortega","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R43-20251007","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/BOR.0000000000001039","article-title":"Autoantibody testing in myositis: an update","volume":"36","author":"McMorrow","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"R44-20251007","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/art.41615","article-title":"Comparison of lesional juvenile myositis and lupus skin reveals overlapping yet unique disease pathophysiology","volume":"73","author":"Turnier","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R45-20251007","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41598-021-04302-8","article-title":"Transcriptomes of peripheral blood mononuclear cells from juvenile dermatomyositis patients show elevated inflammation even when clinically inactive","volume":"12","author":"Roberson","year":"2022","journal-title":"Sci Rep"},{"key":"R46-20251007","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.168.8.4154","article-title":"Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis","volume":"168","author":"Tezak","year":"2002","journal-title":"J Immunol"},{"key":"R47-20251007","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"R48-20251007","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/BOR.0000000000000816","article-title":"Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy","volume":"33","author":"Kim","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"R49-20251007","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of Type I and Type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R50-20251007","doi-asserted-by":"crossref","first-page":"e179875","DOI":"10.1172\/jci.insight.179875","article-title":"Tape strip expression profiling of juvenile dermatomyositis skin reveals mitochondrial dysfunction contributing to disease endotype","volume":"10","author":"Turnier","year":"2025","journal-title":"JCI Insight"},{"key":"R51-20251007","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-020-02160-9","article-title":"Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies","volume":"22","author":"Kim","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R52-20251007","doi-asserted-by":"crossref","first-page":"101976","DOI":"10.1016\/j.berh.2024.101976","article-title":"Personalised medicine in juvenile dermatomyositis: from novel insights in disease mechanisms to changes in clinical practice","volume":"38","author":"Veldkamp","year":"2024","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R53-20251007","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40272-024-00658-2","article-title":"Juvenile dermatomyositis: updates in pathogenesis and biomarkers, current treatment, and emerging targeted therapies","volume":"27","author":"Kim","year":"2025","journal-title":"Paediatr Drugs"},{"key":"R54-20251007","doi-asserted-by":"crossref","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"R55-20251007","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon beta in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"R56-20251007","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3899\/jrheum.2024-0806","article-title":"Correlation between interferon response gene score and disease activity in juvenile dermatomyositis","volume":"52","author":"MacMahon","year":"2025","journal-title":"J Rheumatol"},{"key":"R57-20251007","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard-2022-223628","article-title":"2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice","volume":"82","author":"Rodriguez-Carrio","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R58-20251007","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3899\/jrheum.2025-0395","article-title":"Interferon response gene score in juvenile dermatomyositis","volume":"52","author":"Kim","year":"2025","journal-title":"J Rheumatol"},{"key":"R59-20251007","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3899\/jrheum.181275","article-title":"Endothelial activation markers as disease activity and damage measures in juvenile dermatomyositis","volume":"47","author":"Kishi","year":"2020","journal-title":"J Rheumatol"},{"key":"R60-20251007","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/art.41236","article-title":"Endothelial and inflammation biomarker profiles at diagnosis reflecting clinical heterogeneity and serving as a prognostic tool for treatment response in two independent cohorts of patients with juvenile dermatomyositis","volume":"72","author":"Wienke","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R61-20251007","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/rheumatology\/keaa270","article-title":"Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk","volume":"60","author":"Wienke","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R62-20251007","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.38676","article-title":"Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis","volume":"66","author":"Bellutti Enders","journal-title":"Arthritis Rheumatol"},{"key":"R63-20251007","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/art.40881","article-title":"Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation","volume":"71","author":"Wienke","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R64-20251007","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/rheumatology\/keab601","article-title":"Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response","volume":"61","author":"Lerkvaleekul","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R65-20251007","doi-asserted-by":"crossref","first-page":"e176963","DOI":"10.1172\/jci.insight.176963","article-title":"Coordinated immune dysregulation in juvenile dermatomyositis revealed by single-cell genomics","volume":"9","author":"Rabadam","year":"2024","journal-title":"JCI Insight"},{"key":"R66-20251007","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.3390\/ijms26104950","article-title":"Disease activity-dependent siglec-1 expression on monocyte subsets of patients with idiopathic inflammatory myopathies","volume":"26","author":"Barath","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R67-20251007","first-page":"keaf227","article-title":"Targeting interferon responses in juvenile dermatomyositis: siglec-1 as an in vitro biomarker for jak inhibitor efficacy","author":"Veldkamp","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R68-20251007","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/rheumatology\/kead186","article-title":"Effect of type I interferon on engineered pediatric skeletal muscle: a promising model for juvenile dermatomyositis","volume":"63","author":"Covert","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R69-20251007","doi-asserted-by":"crossref","first-page":"e11760","DOI":"10.1002\/acr2.11760","article-title":"Interferon-beta-induced injury during pediatric muscle differentiation: insight into juvenile dermatomyositis pathogenesis","volume":"7","author":"Covert","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"R70-20251007","doi-asserted-by":"crossref","first-page":"SI240","DOI":"10.1093\/rheumatology\/keae082","article-title":"Genetic changes from type I interferons and JAK inhibitors: clues to drivers of juvenile dermatomyositis","volume":"63","author":"Covert","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R71-20251007","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/art.41639","article-title":"The vasculopathy of juvenile dermatomyositis: endothelial injury, hypercoagulability, and increased arterial stiffness","volume":"73","author":"Papadopoulou","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R72-20251007","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM197202172860701","article-title":"Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy","volume":"286","author":"Whitaker","year":"1972","journal-title":"N Engl J Med"},{"key":"R73-20251007","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/art.1780300513","article-title":"Activation of complement and coagulation in juvenile dermatomyositis","volume":"30","author":"Scott","year":"1987","journal-title":"Arthritis Rheum"},{"key":"R74-20251007","first-page":"801","article-title":"Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis","volume":"31","author":"Sallum","year":"2004","journal-title":"J Rheumatol"},{"key":"R75-20251007","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1740-2557-3-2","article-title":"Endothelial cell activation and neovascularization are prominent in dermatomyositis","volume":"3","author":"Nagaraju","year":"2006","journal-title":"J Autoimmune Dis"},{"key":"R76-20251007","doi-asserted-by":"crossref","first-page":"278S","DOI":"10.1042\/bst019278s","article-title":"Expression of drug resistance in Chinese hamster ovary (CHO) cells following X-ray pretreatment in vitro","volume":"19","author":"McClean","year":"1991","journal-title":"Biochem Soc Trans"},{"key":"R77-20251007","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/nan.12498","article-title":"Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis","volume":"45","author":"Soponkanaporn","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R78-20251007","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1002\/art.34606","article-title":"Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126","volume":"64","author":"Kim","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R79-20251007","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/art.1780250203","article-title":"Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis","volume":"25","author":"Crowe","year":"1982","journal-title":"Arthritis Rheum"},{"key":"R80-20251007","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/art.22993","article-title":"Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients","volume":"57","author":"Miles","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R81-20251007","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/art.23012","article-title":"International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials","volume":"57","author":"Wedderburn","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"(Pt 7)","key":"R82-20251007","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/brain\/aww122","article-title":"Microvascular alterations and the role of complement in dermatomyositis","volume":"139","author":"Lahoria","year":"2016","journal-title":"Brain"},{"key":"R83-20251007","doi-asserted-by":"crossref","first-page":"952699","DOI":"10.3389\/fneur.2022.952699","article-title":"Impairment of muscular endothelial cell regeneration in dermatomyositis","volume":"13","author":"Lemmer","year":"2022","journal-title":"Front Neurol"},{"key":"R84-20251007","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s41927-025-00504-z","article-title":"Microvascular abnormalities between anti-TIF1-gamma-associated dermatomyositis with and without malignancy","volume":"9","author":"Mumtaz","year":"2025","journal-title":"BMC Rheumatol"},{"key":"R85-20251007","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12964-025-02159-2","article-title":"Mda5 protein mediating persistent ER stress\/unfolded protein response contributes to endothelial-mesenchymal-transition of lung microvascular endothelial cell in dermatomyositis","volume":"23","author":"Zhao","year":"2025","journal-title":"Cell Commun Signal"},{"key":"R86-20251007","doi-asserted-by":"crossref","first-page":"e200116","DOI":"10.1212\/NXI.0000000000200116","article-title":"Jo-1 antibodies from myositis induce complement-dependent cytotoxicity and TREM-1 upregulation in muscle endothelial cells","volume":"10","author":"Honda","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R87-20251007","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.12444","article-title":"The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes","volume":"280","author":"Rider","year":"2016","journal-title":"J Intern Med"},{"key":"R88-20251007","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/nan.12528","article-title":"Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features","volume":"45","author":"Yasin","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R89-20251007","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3899\/jrheum.120555","article-title":"Baff expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies","volume":"40","author":"Lopez De Padilla","year":"2013","journal-title":"J Rheumatol"},{"key":"R90-20251007","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3390\/diagnostics13162626","article-title":"B cell lymphocytosis in juvenile dermatomyositis","volume":"13","author":"Costin","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R91-20251007","doi-asserted-by":"crossref","first-page":"902232","DOI":"10.3389\/fimmu.2022.902232","article-title":"Multimodal single-cell sequencing identifies cellular immunophenotypes associated with juvenile dermatomyositis disease activity","volume":"13","author":"Neely","year":"2022","journal-title":"Front Immunol"},{"key":"R92-20251007","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3389\/fimmu.2018.01372","article-title":"CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through toll-like receptor 7 and interferon-alpha","volume":"9","author":"Piper","year":"2018","journal-title":"Front Immunol"},{"key":"R93-20251007","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/art.42989","article-title":"TLR7\/8 activation in immune cells and muscle by RNA-containing immune complexes: role in inflammation and the pathogenesis of myositis","volume":"77","author":"Wu","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R94-20251007","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/art.42785","article-title":"Prognostic role of interferon-lambda3 in antimelanoma differentiation-associated gene 5-positive dermatomyositis-associated interstitial lung disease","volume":"76","author":"Fukada","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R95-20251007","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/art.42972","article-title":"Muscle tissue transcriptome of idiopathic inflammatory myopathy reflects the muscle damage process by monocytes and presence of skin lesions","volume":"77","author":"Izuka","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R96-20251007","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/rheumatology\/keab371","article-title":"Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease","volume":"61","author":"Gono","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R97-20251007","doi-asserted-by":"crossref","first-page":"1567833","DOI":"10.3389\/fimmu.2025.1567833","article-title":"The role of monocytes and macrophages in idiopathic inflammatory myopathies: Insights into pathogenesis and potential targets","volume":"16","author":"Izuka","year":"2025","journal-title":"Front Immunol"},{"key":"R98-20251007","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/art.41078","article-title":"Neutrophil extracellular traps in tissue and periphery in juvenile dermatomyositis","volume":"72","author":"Duvvuri","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R99-20251007","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1097\/RHU.0000000000001772","article-title":"Low-density granulocytes and neutrophil extracellular traps as biomarkers of disease activity in adult inflammatory myopathies","volume":"28","author":"Torres-Ruiz","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"R100-20251007","doi-asserted-by":"crossref","first-page":"114144","DOI":"10.1016\/j.intimp.2025.114144","article-title":"CGAS-STING mediates neutrophil extracellular traps-induced EMT in myositis-associated interstitial lung disease: STING as a potential therapeutic target","volume":"149","author":"Feng","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"R101-20251007","doi-asserted-by":"crossref","DOI":"10.1007\/s10753-024-02220-1","article-title":"Colchicine alleviates interstitial lung disease in an experimental autoimmune myositis murine model by inhibiting the formation of neutrophil extracellular traps","author":"Li","year":"2024","journal-title":"Inflammation"},{"key":"R102-20251007","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/cei\/uxae028","article-title":"Neutrophil extracellular traps induce pyroptosis of pulmonary microvascular endothelial cells by activating the NLRP3 inflammasome","volume":"217","author":"Zhao","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"R103-20251007","doi-asserted-by":"crossref","first-page":"134189","DOI":"10.1172\/jci.insight.134189","article-title":"Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies","volume":"5","author":"Seto","year":"2020","journal-title":"JCI Insight"},{"key":"R104-20251007","doi-asserted-by":"crossref","first-page":"103061","DOI":"10.1016\/j.jaut.2023.103061","article-title":"Role of mitochondria in the myopathy of juvenile dermatomyositis and implications for skeletal muscle calcinosis","volume":"138","author":"Duvvuri","year":"2023","journal-title":"J Autoimmun"},{"key":"R105-20251007","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1038\/s41467-024-49460-1","article-title":"IFN-gamma causes mitochondrial dysfunction and oxidative stress in myositis","volume":"15","author":"Abad","year":"2024","journal-title":"Nat Commun"},{"key":"R106-20251007","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1038\/s41598-022-09943-x","article-title":"The SNPs of mitochondrial DNA displacement loop region and mitochondrial DNA copy number associated with risk of polymyositis and dermatomyositis","volume":"12","author":"Zhao","year":"2022","journal-title":"Sci Rep"},{"key":"R107-20251007","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/ard-2022-223469","article-title":"Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis","volume":"82","author":"Wilkinson","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R108-20251007","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"key":"R109-20251007","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R110-20251007","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R111-20251007","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/acr.25393","article-title":"Childhood arthritis and rheumatology research alliance biologic disease-modifying antirheumatic drug consensus treatment plans for refractory moderately severe juvenile dermatomyositis","volume":"76","author":"Tarvin","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R112-20251007","doi-asserted-by":"crossref","first-page":":1055","DOI":"10.1016\/j.ard.2025.04.024","article-title":"Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society\/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force","volume":"84","author":"Ravelli","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R113-20251007","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41577-023-00877-7","article-title":"Protein kinases: drug targets for immunological disorders","volume":"23","author":"Castelo-Soccio","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"R114-20251007","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12969-021-00637-8","article-title":"Jak inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology","volume":"19","author":"Ll Wilkinson","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"R115-20251007","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/1744666X.2024.2312819","article-title":"Updates on efficacy and safety Janus kinase inhibitors in juvenile dermatomyositis","volume":"20","author":"Kim","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"R116-20251007","doi-asserted-by":"crossref","first-page":"152426","DOI":"10.1016\/j.semarthrit.2024.152426","article-title":"Treatment with Janus kinase inhibitors in juvenile dermatomyositis: a review of the literature","volume":"66","author":"Sener","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"R117-20251007","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14656566.2024.2392021","article-title":"Current evidence for Janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons","volume":"25","author":"Wallwork","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"R118-20251007","doi-asserted-by":"crossref","first-page":"keaf086","DOI":"10.1093\/rheumatology\/keaf086","article-title":"Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PRES providers","author":"Sherman","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R119-20251007","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(24)02071-3","article-title":"Efficacy, safety, and target engagement of dazukibart, an IFN-beta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Fiorentino","year":"2025","journal-title":"Lancet"},{"key":"R120-20251007","doi-asserted-by":"crossref","first-page":"e2024067481","DOI":"10.1542\/peds.2024-067481","article-title":"Monoclonal antibody targeting IFN-beta for the treatment of NXP2-positive ulcerative juvenile dermatomyositis","volume":"155","author":"Guirguis","year":"2025","journal-title":"Pediatrics"},{"key":"R121-20251007","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaad.2024.07.1491","article-title":"Anifrolumab in recalcitrant cutaneous dermatomyositis: a multicenter retrospective cohort study","volume":"91","author":"Shaw","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"R122-20251007","article-title":"A novel treatment for refractory dermatomyositis: a systematic review of anifrolumab and dermatomyositis","author":"Srivatsa","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"R123-20251007","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamadermatol.2023.4744","article-title":"Rapid improvement in recalcitrant cutaneous juvenile dermatomyositis with anifrolumab treatment","volume":"160","author":"Shaw","year":"2024","journal-title":"JAMA Dermatol"},{"key":"R124-20251007","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ard.2025.02.002","article-title":"Rapid clinical and transcriptomic response to anifrolumab in refractory anti-TIF1gamma-positive juvenile dermatomyositis","volume":"84","author":"Triaille","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R125-20251007","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/bjd\/ljaf064","article-title":"Improvement in dermatomyositis-associated muscle disease with anifrolumab","volume":"192","author":"Shayegan","year":"2025","journal-title":"Br J Dermatol"},{"key":"R126-20251007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10875-024-01826-2","article-title":"Normalized interferon signatures and clinical improvements by IFNAR1 blocking antibody (anifrolumab) in patients with Type I interferonopathies","volume":"45","author":"Kretzschmar","year":"2024","journal-title":"J Clin Immunol"},{"key":"R127-20251007","doi-asserted-by":"crossref","DOI":"10.1002\/art.43145","article-title":"Sustained interferon signature suppression with anifrolumab in a patient with sting-associated vasculopathy with onset in infancy refractory to JAK inhibitor and dazukibart therapy","author":"Alehashemi","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R128-20251007","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar3909","article-title":"Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity","volume":"14 Suppl 5","author":"Mei","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R129-20251007","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R130-20251007","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete b cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"key":"R131-20251007","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the reset-myositis phase I\/II trial","volume":"32","author":"Volkov","year":"2024","journal-title":"Mol Ther"},{"key":"R132-20251007","doi-asserted-by":"crossref","first-page":"4890.e9","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"R133-20251007","doi-asserted-by":"crossref","first-page":"e2315990121","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-RP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R134-20251007","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"R135-20251007","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"R136-20251007","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R137-20251007","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"Muller","year":"2025","journal-title":"Nat Med"},{"key":"R138-20251007","first-page":"1560","article-title":"Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R139-20251007","doi-asserted-by":"crossref","first-page":"e003093","DOI":"10.1136\/rmdopen-2023-003093","article-title":"Defining criteria for disease activity states in juvenile dermatomyositis based on the juvenile dermatomyositis activity index","volume":"10","author":"Rosina","year":"2024","journal-title":"RMD Open"},{"key":"R140-20251007","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1093\/rheumatology\/keae392","article-title":"Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis","volume":"63","author":"Papadopoulou","year":"2024","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:01:14Z","timestamp":1759813274000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":140,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001112","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}